Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;126(12):1795–1805. doi: 10.1038/s41416-022-01744-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a ROC curve analysis of CTSF, FBLN1, carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCC) and cytokeratin fragment 21–1 (CYFRA21-1) for differentiating non-small cell lung cancer brain metastasis (LCBM) and non-small cell lung cancer (NSCLC) patients [single organ liver metastasis (LM), single organ bone metastasis (BoM), advanced NSCLC without distant organ metastasis (ALC) and early-stage NSCLC (ELC)] in cohort 2. ROC curve analysis of CTSF, FBLN1 and combination in patients with LCBM versus controls [LM, BoM, ALC, ELC, primary brain tumours (PBT) and healthy group (HG)] in the training dataset (b) and validation dataset (c). d The verification results of the validation dataset using the prediction model and cut-off value. TP true positive, FP false positive, FN false negative, TN true negative. Sensitivity = TP/(TP + FN) *100% = 86.36%; Specificity = TN/ (TN + FP) *100% = 74.14%.